Galantamine slows functional decline in Alzheimer's disease
As Alzheimer's disease progresses, patients become unable to
carry out their usual daily activities. The effect of treatment on the
course of functional decline is therefore an important outcome measure
in dementia studies. Wilcock et al (p 1445) report on the six month
efficacy and safety of galantamine, a new treatment for Alzheimer's
disease. Galantamine significantly improved cognitive and global
function compared with placebo. Moreover, relative to placebo,
galantamine slowed the progression of functional decline. Most patients
tolerated galantamine well.
CiteULike 
Complore 
Connotea 
Del.icio.us 
Digg 
Reddit 
StumbleUpon 
Technorati What's this?
Relevant Article
- Efficacy and safety of galantamine in patients with mild to moderate Alzheimer's disease: multicentre randomised controlled trial
- Gordon K Wilcock, Sean Lilienfeld, and Els Gaens
BMJ 2000 321: 1445.[Abstract] [Full Text] [PDF]
This Article
- Respond to this article
- Alert me when this article is cited
- Alert me when responses are posted
- Alert me when a correction is posted
Services
- Email this article to a friend
- Find similar articles in BMJ
- Find similar articles in PubMed
- Add article to my folders
- Download to citation manager
- Request Permissions
Citing Articles
Google Scholar
PubMed
Related Content
Bookmark with
What's new
Latest blogs
Find BMJ on:
Services
Tools
Online poll
Resources
Rapid responses for this article
There are no rapid responses for this article. Print issues
